First Eagle Investment Management LLC lowered its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO – Free Report) by 35.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 354,435 shares of the medical instruments supplier’s stock after selling 198,435 shares during the quarter. First Eagle Investment Management LLC owned about 0.84% of AngioDynamics worth $5,451,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. White Pine Capital LLC purchased a new position in AngioDynamics in the third quarter valued at approximately $2,237,000. Russell Investments Group Ltd. increased its position in shares of AngioDynamics by 7.0% during the third quarter. Russell Investments Group Ltd. now owns 75,085 shares of the medical instruments supplier’s stock valued at $1,155,000 after buying an additional 4,895 shares during the period. State of Wyoming increased its position in AngioDynamics by 166.6% during the 3rd quarter. State of Wyoming now owns 14,750 shares of the medical instruments supplier’s stock valued at $227,000 after buying an additional 9,217 shares in the last quarter. Pinnacle Wealth Planning Services Inc. bought a new stake in shares of AngioDynamics in the third quarter worth approximately $40,000. Finally, Integrated Wealth Concepts LLC purchased a new position in shares of AngioDynamics in the second quarter worth approximately $38,000. Institutional investors own 89.43% of the company’s stock.
Insider Buying and Selling at AngioDynamics
In related news, CFO Stephen Trowbridge sold 23,615 shares of the business’s stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $12.27, for a total transaction of $289,756.05. Following the completion of the sale, the chief financial officer owned 280,461 shares in the company, valued at $3,441,256.47. The trade was a 7.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.00% of the company’s stock.
AngioDynamics Stock Performance
AngioDynamics (NASDAQ:ANGO – Get Free Report) last posted its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.49%. The company had revenue of $80.92 million for the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Sell-side analysts anticipate that AngioDynamics, Inc. will post -0.27 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have commented on ANGO shares. Canaccord Genuity Group restated a “buy” rating and set a $20.00 price objective on shares of AngioDynamics in a report on Friday, October 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a report on Thursday, October 15th. Zacks Research upgraded shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. HC Wainwright decreased their price target on shares of AngioDynamics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, October 13th. Finally, Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, AngioDynamics presently has a consensus rating of “Moderate Buy” and an average target price of $19.00.
AngioDynamics Company Profile
AngioDynamics, Inc. develops, manufactures and markets medical devices used in minimally invasive procedures. Its products are designed for clinicians in areas including vascular access, peripheral vascular disease and oncology. The company’s offerings include vascular access devices such as ports and catheters, as well as technologies used in vascular intervention and cancer treatment. These include the Auryon atherectomy system, which is used to treat certain peripheral arterial conditions, and the NanoKnife System, which uses irreversible electroporation in tumor ablation procedures.
Recommended Stories
- Five stocks we like better than AngioDynamics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO – Free Report).
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
